reatment with 00 mg of pioglitazone hydrochloride or placebo once daily. Therapy with any previous antidiabetic agent was discontinued six weeks prior to the double-blind period. Treatment with 00 mg of pioglitazone hydrochloride produced statistically significant improvements in HbA0c and FPG at endpoint compared to placebo (see Table 00). * Adjusted for baseline, pooled center, and pooled center by treatment interaction †p ≤ 0.000 vs. placebo Table 00. Glycemic Parameters in a 00-Week Placebo-Controlled Monotherapy Trial Placebo Pioglitazone Hydrochloride 00 mg Once Daily Total Population HbA0c (%) N=00 N=00